Skip to main content
. Author manuscript; available in PMC: 2020 Aug 31.
Published in final edited form as: Curr Cancer Drug Targets. 2012 May;12(4):356–371. doi: 10.2174/156800912800190901

Fig. (1).

Fig. (1).

Oxaliplatin pathways: thin dotted arrows indicate pathways that are not deemed relevant in oxaliplatin DDR compared with cisplatin (this diagram has been reproduced with modifications from http://www.pharmgkb.org. Permission has been given by PharmGKB and Stanford University; copyright PharmGKB).